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A Critical Role for Thioredoxin-
Interacting Protein in Diabetes-
Related Impairment of
Angiogenesis
Impaired angiogenesis in ischemic tissue is
a hallmark of diabetes. Thioredoxin-interacting
protein (TXNIP) is an exquisitely glucose-sensitive
gene that is overexpressed in diabetes. As TXNIP
modulates the activity of the key angiogenic
cytokine vascular endothelial growth factor (VEGF),
we hypothesized that hyperglycemia-induced
dysregulation of TXNIP may play a role in the
pathogenesis of impaired angiogenesis in diabetes.
In the current study, we report that high glucose–
mediated overexpression of TXNIP induces
a widespread impairment in endothelial cell (EC)
function and survival by reducing VEGF production
and sensitivity to VEGF action, ﬁndings that are
rescued by silencing TXNIP with small interfering
RNA. High glucose–induced EC dysfunction was
recapitulated in normal glucose conditions by
overexpressing either TXNIP or a TXNIP C247S
mutant unable to bind thioredoxin, suggesting that
TXNIP effects are largely independent of thioredoxin
activity. In streptozotocin-induced diabetic mice,
TXNIP knockdown to nondiabetic levels rescued
diabetes-related impairment of angiogenesis,
arteriogenesis, blood ﬂow, and functional recovery
in an ischemic hindlimb. These ﬁndings were
associated with in vivo restoration of VEGF
production to nondiabetic levels. These data
implicate a critical role for TXNIP in diabetes-related
impairment of ischemia-mediated angiogenesis and
identify TXNIP as a potential therapeutic target for
the vascular complications of diabetes.
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A major part of the morbidity and mortality of diabetes
arises from its vascular complications, of which impaired
angiogenesis is an important feature (1). Patients with
diabetes have impaired collateral development following
vascular occlusion (2), poor wound healing, and increased
rates of peripheral limb amputation (3). The impairment
of ischemia-induced angiogenesis in diabetes is associ-
ated with reduced vascular endothelial growth factor
(VEGF) production—a phenotype remedied by VEGF
gene therapy (4). Monocytes isolated from diabetic
individuals exhibit reduced sensitivity to the promi-
gratory effects of VEGF, further highlighting a central
role for impaired VEGF signaling in the disordered an-
giogenesis of diabetes (5). However, to date, the funda-
mental mechanisms underlying diabetes-related
impairment of endothelial cell (EC) function and
ischemia-mediated angiogenesis, including the role of
hyperglycemia, are incompletely understood.
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Thioredoxin-interacting protein (TXNIP) is a multi-
functional protein involved in the regulation of cellular
homeostasis (6). TXNIP is an exquisitely glucose-
inducible gene as a result of a carbohydrate response
element in the promoter (7) and it is overexpressed in
both diabetic animals and humans (8,9). TXNIP has been
shown to reversibly bind thioredoxin-1 (TRX1), a ubiq-
uitous oxidoreductase with antioxidant activity, in vitro
(10). However, its ability to antagonize TRX1 in vivo
remains unclear (11,12), and it is now appreciated that
TXNIP may exert some of its effects via redox-
independent mechanisms (13,14). More recently, TXNIP
has been shown to bind mitochondrial thioredoxin-2
(TRX2) to induce apoptosis (15). TXNIP is increasingly
implicated as a key regulator of angiogenesis (6,10). We
previously identiﬁed a central role for TXNIP in VEGF-
mediated EC migration, which is a key angiogenesis event
(10). Indeed, the promigratory effects of angiogenic
growth factors, such as VEGF, are mediated in part by
their repression of TXNIP (10). We therefore hypothe-
sized that hyperglycemia-mediated overexpression of
TXNIP plays a causal role in impaired angiogenesis in
diabetes.
Here, we report that elevated glucose concentrations
induce a TXNIP-dependent impairment in EC function
and VEGF signaling. We also demonstrate that targeted
knockdown of TXNIP reverses the high glucose–induced
impairment of EC angiogenic function, VEGF production,
and sensitivity to VEGF action. Furthermore, we report
that normalization of TXNIP expression to nondiabetic
levels by small interfering RNA (siRNA) delivery in vivo
rescues diabetes-related impairment of ischemia-induced
angiogenesis.
RESEARCH DESIGN AND METHODS
Cell Culture and Angiogenesis Assays
Human umbilical vein ECs (HUVECs) and human coro-
nary artery ECs (HCAECs) were cultured in MesoEndo
Media (Cell Applications) in normal glucose conditions
(5 mmol/L). For high glucose and mannitol conditions,
media was supplemented with D-glucose to a ﬁnal con-
centration of 15 or 25 mmol/L, or D-mannitol to a ﬁnal
concentration of 5 mmol/L D-glucose, 20 mmol/L
D-mannitol. ECs (#passage 4) were treated with glucose
for 24 h, and then plated for migration and proliferation
assays for a further 24 h in their glucose conditions. For
tubulogenesis assays, ECs were pretreated with glucose
for 42 h, and then assayed for a further 6 h. Therefore,
ECs were exposed to glucose conditions for 48 h unless
otherwise indicated.
Cell migration was assessed by a modiﬁed Boyden
chamber assay with cells visualized by DAPI staining
(16). Exogenous human VEGF165 (10 ng/mL, R&D Sys-
tems) or VEGF monoclonal antibody (1 mg/mL, Sigma-
Aldrich) was added where indicated. Cell proliferation
was assessed by ﬂow cytometry analysis (FC500;
Beckman Coulter) of 5-ethynyl-2-deoxyuridine (EdU)
incorporation (Life Technologies). Tubulogenesis on
growth factor–reduced Matrigel (BD Biosciences) (16)
was assessed by photomicrography and measured by
tubule area. All results were conﬁrmed by also measuring
both tubule length and branch points. Nitric oxide was




Total TRX activity was determined using the insulin
disulﬁde reduction assay (17) with removal of the
dithiothreitol and 70°C denaturation steps to enhance
the assay’s sensitivity to available TRX (18). This assay
does not discriminate between TRX1 and mitochondrial
TRX2, so the results are referred to as total TRX activ-
ity. Glutathione Assay Kit (BioVision) and ThioGlo-5
(Sigma-Aldrich) were used to determine reduced:oxi-
dized glutathione (GSH:GSSG) ratios and total cellular
thiols. Iron (III) and total iron were determined by
electron paramagnetic resonance and inductively cou-
pled plasma atomic emission spectroscopy, respectively
(19,20).
Gene Modulation
Human TXNIP cDNA (Genbank Accession: NM_006472)
or a TXNIP C247S mutant was overexpressed from the
pCI-neo plasmid (Promega). Plasmid containing no insert
was used as a control. Duplex siRNA to human TXNIP
and a scrambled (SCR) sequence were used for in vitro
gene silencing experiments (10). Plasmids and siRNA
were transfected into ECs using Lipofectamine 2000 (Life
Technologies). For in vivo studies, short-hairpin siRNA to
murine TXNIP was expressed from pRNA-U6.1/neo
(GenScript) and a SCR hairpin was used as a control.
Gene Expression
Quantitative PCR was performed using iQ SYBR-Green
Supermix and iCycler Real-time PCR Detection System
(Bio-Rad) and gene expression calculated using b-actin as
a reference gene (21).
Protein Studies
Coimmunoprecipitation and Western blot analyses were
performed using commercially available kits (Life Tech-
nologies). Membranes were probed for TXNIP (rabbit
anti-VDUP1, 1:500; Life Technologies), TRX1 (rabbit
anti-TRX1, 1:1,000; Abcam), TRX2 (rabbit anti-TRX2,
1:500; Novus Biologicals), VEGF (rabbit anti-VEGF,
1:1,000; Abcam), and endothelial nitric oxide synthase
(eNOS) (mouse anti-eNOS, 1:1,000; Cell Applications).
Enhanced chemiluminescence detection was performed
using Quantity One (Bio-Rad) and densitometry by
ImageJ software. VEGF165, tumor necrosis factor-a, in-
terleukin (IL)-1b, IL-8, and transforming growth factor-b
were assessed by ELISA (R&D Systems). Kinase domain
receptor (KDR) (VEGF receptor-2) was assessed by ﬂow
cytometry.
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Apoptosis Assays
Apoptosis and necrosis were assessed after 24 h of high
glucose exposure by ﬂow cytometry analysis of Annexin-
V-FITC and propidium iodide-PE staining, respectively
(Sigma-Aldrich). Caspase 3/7 activation and DNA frag-
mentation by TUNEL assay were assessed using com-
mercially available kits (Promega).
Diabetic Model of Murine Hindlimb Ischemia
All animal experiments were conducted with approval
from the Sydney Local Health District Animal Ethics
Committee. Diabetes was induced in 5-week-old male
C57BL/6J mice by a bolus intraperitoneal injection of
streptozotocin (STZ) (165 mg/g in citrate buffer, pH 4.5).
Blood glucose levels were monitored with an Accu-Chek
glucometer. At 7 weeks of age, the mice underwent
unilateral hindlimb ischemia (in a subset of experiments
ischemia was introduced at 13 weeks of age to assess the
possibility of STZ toxicity). In brief, under methoxyﬂu-
rane inhalation anesthesia, the femoral vein and super-
ﬁcial and deep femoral arteries were ligated with 7–0 silk
sutures. The vessels were then excised down to the sa-
phenous artery. A sham procedure was performed on the
contralateral limb. Laser Doppler perfusion imaging was
performed on anesthetized mice prior to surgery, post-
surgery, and on days 3, 7, and 10 (moorLDI2-IR, Moor
Instruments, U.K.). pRNA-U6.1/neo encoding hairpin
siRNA to murine TXNIP (or SCR control) was resus-
pended in TransIT IN VIVO Reagent at 1 mg/mL (Mirus
Bio). After imaging on days 0, 3, and 7, 50 mg of plasmid
was delivered to the adductor muscle at four locations
(12.5 mL/site). On days 0, 3, 7, and 10, pedal reﬂexes and
tissue ischemia were assessed by eye (22).
Isolation of Murine Hindlimb ECs
ECs were isolated from hindlimb skeletal muscle using
CD146 magnetic microbeads (Miltenyi Biotec) and their
identity conﬁrmed by von Willebrand factor (vWF)
(Abcam), PECAM (Abcam), and BS1-lectin (Sigma-
Aldrich) staining.
Immunohistochemistry
Adductor muscles were ﬁxed in parafﬁn, sectioned, and
stained to detect capillary ECs using vWF (Dako) (16)
and arterioles by smooth muscle a-actin (Sigma-Aldrich).
Capillary-to-myocyte ratio, arteriole-to-myocyte ratio,
and vessel diameter were calculated using ImageJ
software.
Statistical Analyses
All in vitro experiments were performed on at least three
separate occasions using three individual EC donors, with
intra-assay replicates of n $ 3 for all assays (excluding
ELISA, n = 2). All animal experiments had 8–12 mice per
group, excluding the ex vivo oxidized iron analyses (5–6
per group). Experiments were analyzed using Prism 6 for
Macintosh, version 6.0a software. Results are expressed
as mean 6 SEM. In cell experiments, two data sets were
analyzed by Mann-Whitney test, three or more data sets
were analyzed by Kruskal-Wallis test with Dunn multiple
comparisons, and grouped data were analyzed by two-
way ANOVA with Dunnett multiple comparisons. In
animal experiments, data were analyzed by Mann-
Whitney test, by one-way ANOVA with Holm-Sidak
multiple comparisons, and in grouped data by two-way
ANOVA with Holm-Sidak multiple comparisons. P ,
0.05 was considered signiﬁcant.
RESULTS
Elevated Glucose Concentration Impairs EC Function
and Induces TXNIP
High glucose concentrations of 15 and 25 mmol/L were
associated with dose-dependent impairment of the key
endothelial functions of migration, proliferation, and
tubulogenesis in HUVECs (P , 0.05, Fig. 1A–C). In
parallel, increasing glucose concentrations were associ-
ated with a dose-dependent induction of TXNIP mRNA
(Fig. 1D) and TXNIP protein (Fig. 1E). High glucose did
not lead to changes in TRX1 (Fig. 1F) or TRX2 levels
(Supplementary Fig. 1). However, high glucose conditions
led to a reduction in total TRX activity (P , 0.05) (Fig.
1G), consistent with increased TXNIP expression. Similar
ﬁndings were observed when HCAECs were used (Sup-
plementary Fig. 2).
TXNIP Overexpression Mimics the Effect of High
Glucose Concentrations on EC Function—an Effect
That Is Independent of TRX1 Binding
To investigate if TXNIP induction alone was causal to EC
dysfunction, we overexpressed TXNIP under normal
glucose conditions (5 mmol/L) (Fig. 2A). Overexpression
of wild-type or mutant TXNIP had no effect on TRX1
(Fig. 2A) or TRX2 levels (Supplementary Fig. 1). Over-
expression of wild-type TXNIP was associated with TRX1
binding in coimmunoprecipitation assays (Fig. 2B) and
a marked reduction in TRX activity (P , 0.05) (Fig. 2C).
In contrast, overexpression of a C247S TXNIP mutant,
which is unable to bind TRX1 (Fig. 2B) or TRX2, was not
associated with any impairment in TRX activity (Fig. 2C).
However, overexpression of either wild-type TXNIP or
the C247S TXNIP mutant led to inhibition of HUVEC
migration, proliferation, and tubulogenesis (Fig. 2D–F)
comparable to the impairment seen in hyperglycemia
(Fig. 1). These data suggest that TXNIP induction is
sufﬁcient to impair angiogenic processes and does so
likely via a TRX-independent mechanism. Taken together
with the previous results, these data indicate a key role
for TXNIP in glucose-mediated EC dysfunction.
Gene Silencing of TXNIP Rescues the Impairment of
Angiogenic Processes in High Glucose Conditions
To determine if we could rescue high glucose–induced
impairment of EC angiogenesis, we proceeded to knock-
down TXNIP in HUVEC using siRNA (Fig. 3A). At even
the highest glucose concentration (25 mmol/L), TXNIP
knockdown rescued glucose-induced impairment of
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HUVEC angiogenic function, restoring migration, pro-
liferation, and tubulogenesis to levels of control (mock-
transfected HUVEC in normal 5 mmol/L glucose) (Fig.
3B–D). Similar results were obtained when HCAECs were
assessed (Supplementary Fig. 3). These data suggest that
the suppression of TXNIP can negate the inhibitory
effects of hyperglycemia on EC function and therefore
identify TXNIP as a potential therapeutic target for
modulation of angiogenesis in the context of diabetes.
VEGF Signaling Is Impaired in Hyperglycemia and Is
Restored by Gene Silencing of TXNIP
The key angiogenic cytokine VEGF has been strongly
implicated in the pathogenesis of diabetes-related
impairment in angiogenesis. In HUVECs, high glucose
concentrations (15–25 mmol/L) were associated with
a dose-dependent decrease in VEGF protein expression
(Fig. 4A). However, gene silencing of TXNIP rescued
VEGF expression and secretion to levels above that of
a scrambled siRNA-treated control (Fig. 4B–C). Expres-
sion of KDR, the receptor mediating the proangiogenic
effects of VEGF, was similarly increased by TXNIP
knockdown (Fig. 4D). Consistent with VEGF upregula-
tion of eNOS, TXNIP knockdown was associated with
increased eNOS expression and nitric oxide production
across all glucose conditions (Supplementary Fig. 4A–C).
We also investigated whether TXNIP induction via high
Figure 1—Elevated glucose concentration impairs EC function and induces TXNIP. HUVECs were treated with increasing glucose
concentrations or an osmolar mannitol control. HUVEC angiogenic function was assessed by migration in a modiﬁed Boyden chamber
assay (A), proliferation in an EdU incorporation assay (B), and tubulogenesis in a growth factor-reduced Matrigel assay (C ). Hyper-
glycemic modulation of the thioredoxin system was assessed by quantitative PCR of TXNIP mRNA levels (D), Western blot analysis of
TXNIP protein (E ) and TRX1 protein (F ), and total TRX redox activity as assessed by the insulin disulﬁde reduction assay (G). Results are
representative of at least three separate experiments performed using three individual EC donors. Results are expressed as mean 6
SEM and were analyzed by Kruskal-Wallis analysis with Dunn multiple comparisons. mM, mmol/L. *P < 0.05 compared with the 5 mM
control value.
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glucose or TXNIP silencing affects other proangiogenic
mediators, including tumor necrosis factor-a, IL-1b,
transforming growth factor-b, and IL-8. We did not ob-
serve any change in these cytokine levels in response to
either high glucose concentrations or TXNIP silencing
(data not shown).
Impaired sensitivity to VEGF action has been reported
in diabetes (5). We found that high glucose concen-
trations also inhibited EC sensitivity to the promigratory
action of exogenous VEGF. Whereas HUVECs in 5 mmol/L
glucose showed a 1.8-fold increase in migration upon the
addition of exogenous VEGF, no difference is seen be-
tween cells with or without VEGF at 25 mmol/L glucose
(Fig. 4E). However, TXNIP knockdown abrogated this
impairment, with a twofold increase in migration upon
the addition of VEGF being maintained across all glucose
concentrations. Blocking VEGF action using a mono-
clonal antibody prevented all TXNIP siRNA-induced mi-
gration (Fig. 4D–E), conﬁrming that the effect seen was
VEGF-dependent. Similar results were obtained in
HCAECs (Supplementary Fig. 4D). These data identify
a key role for TXNIP in modulating VEGF-mediated
angiogenesis.
EC Survival Is Impaired in Hyperglycemia and Is
Restored by Gene Silencing of TXNIP
To evaluate the effect of glucose-induced TXNIP on EC
survival, apoptosis was assessed in HUVECs after
Figure 2—TXNIP overexpression replicates the deleterious effects of high glucose concentrations on EC function—an effect independent
of TRX1 binding. HUVECs were transfected with plasmid encoding TXNIP, a TXNIP C247S mutant or empty plasmid (control). A: Western
blot analysis of TXNIP and TXNIP C247S overexpression and TRX1 protein expression. B: Coimmunoprecipitation of TXNIP and TRX1.
C: Total TRX redox activity in HUVEC overexpressing TXNIP, as assessed by the insulin disulﬁde reduction assay. HUVEC angiogenic
function was assessed by migration in a modiﬁed Boyden chamber assay (D), proliferation in an EdU incorporation assay (E), and
tubulogenesis in a growth factor-reduced Matrigel assay (F). Results are representative of at least three separate experiments performed
using three individual EC donors. Results are expressed as mean6 SEM and were analyzed by Kruskal-Wallis analysis with Dunn multiple
comparisons. *P < 0.05 compared with control plasmid value.
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treatment with high glucose concentrations (15–25
mmol/L). Both apoptosis, as measured by annexin-V
staining, caspase 3/7 activity, and TUNEL assay of DNA
fragmentation, and necrosis, as measured by propidium
iodide staining, increased with glucose concentration
after 24 h incubation (P , 0.05) (Fig. 5A–D). However,
TXNIP knockdown by siRNA prevented high glucose–
induced apoptosis (Fig. 5A–C) and necrosis (Fig. 5D).
Figure 3—Gene silencing of TXNIP rescues impairment of EC function and angiogenesis induced by high glucose concentrations.
HUVECs were transfected with siRNA to TXNIP (or SCR control siRNA) and then treated with 5, 15, or 25 mM (mmol/L) glucose.
A: Western blot analysis of TXNIP expression conﬁrms knockdown of endothelial TXNIP expression by siRNA at all glucose concentrations.
Angiogenic function of siRNA-transfected, glucose-treated HUVEC was assessed by migration in a modiﬁed Boyden chamber assay (B),
proliferation in an EdU incorporation assay (C), and tubulogenesis in a growth factor-reduced Matrigel assay (D). Representative pho-
tomicrographs were taken at 203 magniﬁcation. Results are representative of at least three separate experiments performed using three
individual EC donors. Results are expressed as mean 6 SEM and were analyzed by two-way ANOVA with Dunnett multiple comparisons.
*P < 0.05 compared with 5 mM mock-transfection control.
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After 48 h of glucose treatment, induction of apoptosis
was increasingly obscured by cell necrosis (Fig. 5E). Mock
transfections were performed and in all cases the results
were not signiﬁcantly different from SCR siRNA control
(P . 0.3, data not shown), indicating that the apoptosis
and necrosis effects of high glucose and TXNIP silencing
were not confounded by any adverse cellular reaction to
transfection. These data link glucose-mediated induction
of proapoptotic TXNIP to impairment of EC survival.
Diabetes-Related Impairment of Ischemia-Mediated
Angiogenesis Is Rescued by TXNIP Silencing In Vivo
To determine if we could rescue diabetes-related im-
pairment of ischemia-mediated angiogenesis, we elected
to silence TXNIP locally using siRNA in a murine model
of hindlimb ischemia. We conﬁrmed that there were no
signiﬁcant changes in TXNIP expression associated with
hindlimb ischemia when compared with sham-operated
limbs of control mice (data not shown). At day 10, STZ-
induced diabetic mice had higher blood glucose (25 6 4
mmol/L vs.10 6 2 mmol/L) and weighed less (19 6 2 g
vs. 23 6 1 g) than nondiabetic controls. Diabetes was
also associated with increased TXNIP expression in the
hindlimb muscle (P , 0.05) (Fig. 6A–B), and this was
normalized to nondiabetic levels by the intramuscular
injection of TXNIP siRNA-encoding plasmid (Fig. 6C–D).
In addition, TXNIP was speciﬁcally shown to be silenced
in ECs isolated from the ischemic hindlimb (Fig. 6E).
Following the surgical introduction of hindlimb is-
chemia, diabetic mice exhibited a marked impairment of
recovery compared with nondiabetic controls that was
reversed by silencing TXNIP. When the mice were killed
(day 10), blood ﬂow recovery in diabetic mice was half
that of controls, measured as a laser Doppler perfusion
index (LDPI) (blood ﬂow of ischemic vs. nonischemic
hindlimb, 0.28 6 0.04 vs. 0.58 6 0.04, P , 0.05) (Fig.
6F). This observation was associated with a 40 6 8%
reduction in capillary density (P , 0.05) (Fig. 6G) and
poorer pedal reﬂexes and tissue ischemia scores (Fig. 6H–I).
Figure 4—Gene silencing of TXNIP restores glucose-mediated impairment of both VEGF expression and sensitivity to VEGF action.
A: HUVECs were treated with 5, 15, or 25 mM (mmol/L) glucose and analyzed for cellular VEGF by Western blot. HUVECs were transfected
with siRNA to TXNIP (or SCR control siRNA) and then treated with 5, 15, or 25 mM glucose 6 human VEGF165 (10 ng/mL) 6 VEGF
monoclonal antibody (mAb) (1 mg/mL), as indicated, and analyzed for cellular VEGF by Western blot (B), secreted VEGF by ELISA of
overnight growth media (C), and surface KDR expression by ﬂow cytometry (D). E: VEGF-induced migration of siRNA-transfected,
glucose-treated HUVEC was measured in a modiﬁed Boyden chamber assay. Results are representative of at least three separate
experiments performed using three individual EC donors. Results are expressed as mean6 SEM. Results in (A) were analyzed by Kruskal-
Wallis analysis and Dunn multiple comparisons, and in (B–E) by two-way ANOVA with Dunnett multiple comparisons. *P< 0.05 compared
with 5 mM control or 5 mM SCR siRNA control value, #P < 0.05 for TXNIP siRNA compared with SCR siRNA.
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TXNIP knockdown in diabetic mice restored blood ﬂow
recovery (LDPI of 0.48 6 0.05 at day 10) (Fig. 6F) and
capillary density to nondiabetic control levels (Fig. 6G),
improved diabetic pedal reﬂexes, and reduced tissue is-
chemia scores beyond control levels (Fig. 6H–I).
In a separate set of experiments, ischemia was
surgically introduced 6 weeks after diabetes induction
to rule out any effect of STZ toxicity. In agreement
with the above observations, diabetic mice had ele-
vated blood glucose and TXNIP levels (1.3-fold vs.
nondiabetic controls), which was associated with im-
paired blood ﬂow recovery (e.g., at day 7, 0.39 6 0.03
vs. 0.47 6 0.04 controls, P , 0.05) and capillary
density (ischemic vs. nonischemic hindlimb, 0.14 6
0.01 vs. 0.27 6 0.02 controls, P , 0.05). Consistent
with our initial data set, diabetic mice treated with
TXNIP siRNA had improved blood ﬂow recovery
(0.45 6 0.05) and capillary density (0.28 6 0.02) to
levels of the nondiabetic controls (P = 0.29 and 0.82,
respectively).
Gene Silencing TXNIP In Vivo Rescues Impaired VEGF
Production in Diabetes
We next examined the effects of TXNIP knockdown on
VEGF expression in ischemic skeletal muscle. VEGF
protein was reduced in diabetic mice compared with
nondiabetic control levels (P , 0.05) (Fig. 6J). However,
knockdown of TXNIP in diabetic mice restored VEGF
protein to levels not statistically different from controls
(Fig. 6J).
Figure 5—Glucose-mediated impairment of EC survival is rescued by gene silencing of TXNIP. HUVECs were transfected with siRNA to
TXNIP (or SCR control siRNA) and then treated with 5, 15, or 25 mM (mmol/L) glucose. After 24 h of glucose treatment, apoptosis was
assessed by annexin-V staining and ﬂow cytometry analysis (A), caspase 3/7 activity assay (B), and TUNEL DNA fragmentation assay (C).
Necrosis was assessed by propidium iodide staining and ﬂow cytometry analysis after 24 h (D) and 48 h (E) of glucose treatment. Results
are expressed as mean 6 SEM and were analyzed by two-way ANOVA with Dunnett multiple comparisons. *P < 0.05 compared with
5 mM SCR siRNA transfected control value.
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Figure 6—Diabetes-related impairment of ischemia-mediated angiogenesis is rescued by TXNIP silencing in vivo. Unilateral hindlimb
ischemia was surgically introduced in nondiabetic and diabetic male C57BL/6J mice with sham preparation of the contralateral limb.
Plasmid encoding siRNA to murine TXNIP was delivered by intramuscular injection. TXNIP induction and silencing was assessed in
heterogeneous preparations of skeletal muscle tissue by quantitative PCR of TXNIP mRNA (A, C) and Western blot (B, D). E: ECs were
isolated from hindlimb skeletal muscle tissue and assessed for TXNIP protein expression by Western blot analysis. F: Laser Doppler
perfusion imaging was serially performed to determine the blood ﬂow recovery; results are expressed as a ratio of blood perfusion in the
ischemic versus nonischemic hindlimb. Black triangle, nondiabetic mice treated with SCR siRNA; open circle, diabetic mice treated with
SCR siRNA; and black circle, diabetic mice treated with TXNIP siRNA. Images are representative of blood ﬂow recovery at day 10. I,
ischemic, N, nonischemic. G: Capillary density was determined by immunohistochemistry as the ratio of vWF+ vessels per myocyte. Limb
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Gene Silencing of TXNIP In Vivo Does Not Affect TRX
Activity
As the role of TXNIP in modulating TRX activity in vivo
remains debated (6), total TRX activity and related redox
systems were assessed in hindlimb lysates. In our hin-
dlimb ischemia model, we observed no effect of TXNIP
modulation on TRX activity (Fig. 7A). Similarly, TXNIP
knockdown had no effect on the glutathione redox ratio
(GSH:GSSG), total cellular glutathione, total cellular thi-
ols, or the proportion of oxidized iron (III) to total iron
(Fig. 7B–E). These data indicate that the effects of TXNIP
modulation in vivo may be independent of TRX redox
activity and associated oxidative stress.
DISCUSSION
The vascular complications of diabetes are characterized
not only by accelerated atherogenesis but also by im-
paired angiogenesis in response to ischemia. Despite in-
tense scrutiny to date, the mechanisms underlying
disordered EC function and angiogenesis in diabetes re-
main incompletely understood. The salient ﬁndings of
this study are that: 1) high levels of glucose are associ-
ated with induction of TXNIP; 2) overexpression of
TXNIP mimics the impairment in EC function observed
in high glucose conditions; 3) gene silencing of TXNIP
attenuates all glucose-mediated EC angiogenic
dysfunction—a ﬁnding associated with restoration of
VEGF production and action; 4) in vivo normalization of
TXNIP to nondiabetic levels by siRNA rescues diabetes-
related impairment of ischemia-mediated angiogenesis
with restoration of VEGF production; and 5) the effects
of TXNIP on angiogenesis are, at least in part, in-
dependent of TXNIP’s ability to bind to TRX1 and
modulate the activity of thioredoxin. These ﬁndings
demonstrate a direct link between hyperglycemia, EC
dysfunction, and impaired angiogenesis via the induction
of TXNIP, with particular relevance for diabetes-related
impairment of ischemia-induced angiogenesis.
Extensive preclinical and clinical evidence indicates
that hyperglycemia is the key driver of the vascular
complications of diabetes. Intensive blood glucose con-
trol has been demonstrated to reduce diabetes-related
microvascular disease (23,24). In a canine model of re-
peated coronary occlusions, hyperglycemia was causally
linked to reduced collateral development in response to
myocardial ischemia (25). Moreover, poor glycemic con-
trol in diabetic patients (HbA1c .7.5%, 58.5 mmol/mol)
is associated with increased ischemic complications in
peripheral artery disease (26). The pathogenesis of
diabetes-related impairment in ischemia-mediated an-
giogenesis is characterized by reduced VEGF production
and attenuated sensitivity to VEGF action (4,5). How-
ever, to date, the mechanisms underpinning the impaired
VEGF signaling in diabetes remains unclear. We have
previously shown that TXNIP has a role in VEGF-
mediated EC migration (10). As TXNIP is also induced by
glucose and elevated in diabetes, we hypothesized that
hyperglycemia-mediated induction of TXNIP may be
a mechanism underlying the impairment of ischemia-
mediated angiogenesis in diabetes.
In this study, we found that exposure to high glucose
levels led to a derangement in EC angiogenic function via
TXNIP induction. In agreement with previous studies, we
observed that high glucose reduced VEGF production
(27), and that this was accompanied by reduced EC
sensitivity to the promigratory effects of VEGF. In ECs,
VEGF upregulates eNOS leading to increased nitric oxide
production, which induces proangiogenic events (28).
However, high glucose reduces nitric oxide production
and increases eNOS uncoupling (29). We found that
TXNIP gene-silencing rescued high glucose–mediated im-
pairment of eNOS levels and nitric oxide. TXNIP has been
reported to facilitate the release of apoptosis signaling
kinase-1 from TRX1/TRX2, which results in the initiation
of apoptosis (6,15). In our studies, we found that high
glucose was associated with increased apoptosis—a phe-
nomenon that could be rescued by TXNIP gene silencing.
Inhibition of apoptosis may explain, in part, some of the
observed improvements, particularly in regards to pro-
liferation and migration.
We further found that gene silencing of TXNIP res-
cues diabetes-related impairment of ischemia-mediated
angiogenesis in a murine hindlimb ischemia model. Be-
cause TXNIP-knockout animals manifest systemic meta-
bolic derangements that may confound angiogenesis
assessment (12,18), we elected to locally knock down
TXNIP by siRNA at the time of ischemia induction.
TXNIP knockdown in diabetic mice rescued impairment
of blood ﬂow recovery with increases in capillary density,
as well as improved pedal reﬂexes and reduced tissue
ischemia. These results are not confounded by potential
nonspeciﬁc effects of STZ toxicity as a second set of
experiments carried out 6 weeks post-STZ injection re-
capitulated the effects of TXNIP silencing in vivo. Con-
sistent with previous studies (4), we found reduced VEGF
protein levels in the ischemic hindlimb of diabetic mice;
however, TXNIP silencing restored VEGF protein levels
in diabetic mice. These data are consistent with a key role
function was measured by pedal reﬂex score (H) (0 = normal; 1 = plantar but not toe ﬂexion; 2 = no ﬂexion; 3 = dragging of foot) and tissue
ischemia score (I) (0 = no damage; 1 = mild discoloration; 2 = moderate discoloration). Results are representative of 8–12 mice per group
and are expressed as mean 6 SEM. J: VEGF protein expression was assessed by Western blot analysis of heterogeneous preparations of
skeletal muscle tissue. Results in A, B, and E were analyzed by Mann-Whitney test; C, D, G, and J by one-way ANOVA with Holm-Sidak
multiple comparisons; and F, H, and I by two-way ANOVA with Holm-Sidak multiple comparisons. *P < 0.05.
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for TXNIP in diabetes-related impairment of ischemia-
mediated angiogenesis by regulation of VEGF production.
It should be noted that different diabetes complications
have different vascular patterns with reduced angiogen-
esis in ischemia and, paradoxically, increased angiogen-
esis in retinopathy. To date, TXNIP expression has been
found to be elevated in all diabetic tissues assessed, in-
cluding the retina (6,30). Indeed, TXNIP inhibition has
been found to prevent inﬂammation and retinal injury in
early stages of diabetic retinopathy (30).
Overexpression of TRX1 has been reported to enhance
ischemia-mediated angiogenesis in diabetes (31). In our
study, there were no differences in total TRX activity in
diabetic mice compared with controls, and TXNIP
knockdown had no effect on TRX activity in vivo either.
Our ﬁndings in this regard are consistent with previous
data from TXNIP-deﬁcient mice that show no alterations
in TRX1 activity (11,12,18). Moreover, TRX-related redox
buffering systems, including the glutathione system and
the reducing potential of the intracellular iron pool, were
unaffected by TXNIP knockdown. Of note, regardless of
siRNA treatment, diabetic mice had reduced levels of
total cellular thiols compared with nondiabetic mice de-
spite displaying no changes in total TRX activity. This
may, in part, be explained by the observed reduction of
total glutathione levels in diabetic mice. Our data suggest
that the actions of TXNIP in vivo are, at least in part,
independent of its ability to bind TRX1 or TRX2—an
observation supported by our in vitro TXNIP C247S
mutant experiments. However, it has recently been
shown that TRX2 activity is increased in the mitochon-
dria of myocardial cells in TXNIP knockout mice follow-
ing ischemia-reperfusion injury (11), and that deletion of
TRX2 is associated with impaired ischemia-mediated
angiogenesis in the mouse (32). The role of mitochon-
drial TRX2 in diabetes-related impairment of angiogen-
esis in vivo was not explicitly assessed in this study and
remains to be explored.
There is increasing evidence that TXNIP, a member of
the arrestin domain-containing protein family that
modulates G-coupled–receptor signaling (33), regulates
angiogenesis. The C-terminal arrestin domain of TXNIP
Figure 7—Gene silencing of TXNIP is not associated with detectable changes in TRX redox activity in vivo. Unilateral hindlimb ischemia
was surgically introduced in nondiabetic and diabetic male C57BL/6J mice with sham preparation of the contralateral limb. Plasmid
encoding siRNA to murine TXNIP was delivered by intramuscular injection. When the mice were killed, fresh adductor muscle was
prepared on ice. TRX activity, as determined by the insulin disulﬁde reduction assay (A), total cellular thiols (B), total glutathione (C), GSH:
GSSG ratio (D), and the proportion of oxidized iron to total iron (E) in the ischemic hindlimb were assessed in heterogeneous preparations
of skeletal muscle. Results are expressed as mean6 SEM and were analyzed by one-way ANOVA with Holm-Sidak multiple comparisons.
*P < 0.05 to nondiabetic control.
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has been shown to regulate VEGF expression in the mu-
rine lung via hypoxia inducible factor-1a, independent of
TRX1 binding (13). TXNIP has also been shown to mediate
nuclear export of von Hippel–Lindau protein and proan-
giogenic hypoxia inducible factor-1a for degradation (34).
These ﬁndings support our observations that TXNIP’s
regulation of angiogenesis is independent of TRX1 bind-
ing. In addition to our observation that surface-expressed
KDR was increased by TXNIP knockdown, it has been
reported that under normal glucose conditions (5 mmol/L)
the internalization of KDR following acute VEGF
stimulation is reduced by TXNIP siRNA with an associated
reduction in tubulogenesis (35). Interestingly, we did not
observe any signiﬁcant change in VEGF-stimulated EC
migration with TXNIP silencing under normoglycemia.
However, we found that under high glucose conditions,
TXNIP siRNA strikingly rescued hyperglycemic impair-
ment of EC migration. Cumulatively, these results indicate
that TXNIP regulation of the response to VEGF may be
glucose sensitive.
In conclusion, we report a direct role for the induction
of TXNIP in the pathogenesis of diabetes-related im-
pairment of angiogenesis. Gene silencing of TXNIP
abrogates impairment of EC function by high glucose
levels. In vivo, normalization of TXNIP expression by
siRNA rescues diabetes-related impairment of ischemia-
mediated angiogenesis. Interestingly, the antiangiogenic
effects of TXNIP in vivo appear to be independent of
inhibitory action on TRX1. Taken together, these data
implicate a critical role for TXNIP in diabetes-related
impairment of ischemia-induced angiogenesis and iden-
tify TXNIP as a potential therapeutic target for the vas-
cular complications of diabetes.
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